Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Emilio Hospedales"'
Publikováno v:
Cardiology Research. 14:79-85
Autor:
Shenae Samuels, Vivian Hagerty, Tamar Levene, Emilio Hospedales, Amaris L. Alayon, Heather Spader, James A. Botros
Publikováno v:
Child's Nervous System. 37:3881-3889
This study aims to examine the relationship between insurance status, hospital ownership type, and children’s hospital designation with outcomes for pediatric patients undergoing neurosurgical treatment for spasticity. This retrospective cohort stu
Autor:
Zoilo K Suarez, Ana C Finke, Emilio Hospedales, Ernesto Perez, Arya Sharifzadeh, Jennifer Foster, Allison Ferris
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311793
Introduction Pembrolizumab is an immune checkpoint inhibitor that promotes effector T-cell functions on malignant cells by binding to programmed cell death protein 1 (PD-1). Pembrolizumab is well tolerated in most cases with an adverse event profile
Autor:
Amaris L, Alayon, Vivian, Hagerty, Emilio, Hospedales, James, Botros, Tamar, Levene, Shenae, Samuels, Heather, Spader
Publikováno v:
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 37(12)
This study aims to examine the relationship between insurance status, hospital ownership type, and children's hospital designation with outcomes for pediatric patients undergoing neurosurgical treatment for spasticity.This retrospective cohort study